Paxlovid, the oral antiviral made by Pfizer, reduced the risk of COVID-19-related hospitalization or death by 89% in its landmark clinical trial. For anyone caring for an older adult with dementia or cognitive decline, that number matters enormously. In the Phase 2/3 EPIC-HR trial, only 0.8% of patients treated with Paxlovid within three days of symptom onset were hospitalized, compared to 7.0% of those on placebo — a group that also saw seven deaths. The drug, a combination of nirmatrelvir and ritonavir, remains the standard oral antiviral for COVID-19 treatment as of 2025 and is FDA-approved for anyone age 12 and older who is at risk for severe illness.
But that 89% figure comes with important context, especially for the dementia care community. The original trial enrolled unvaccinated participants with no prior infection, all of whom had high-risk conditions like obesity, diabetes, or heart disease. That is not the profile of most older adults today, many of whom have been vaccinated or previously infected. Research from UCLA Health found that Paxlovid’s effect on hospitalization among vaccinated older adults is “at best four times weaker” than the original trial suggested. This article breaks down what Paxlovid actually does, how well it works in real-world conditions, its limitations around Long COVID, and what caregivers of people with dementia need to know about timing, drug interactions, and rebound risk.
Table of Contents
- How Does Paxlovid Cut COVID Hospitalization Risk by 89%?
- Real-World Effectiveness in Vaccinated and Older Adults
- Why Timing Matters More Than Anything Else
- Drug Interactions Caregivers Must Watch For
- The Rebound Problem and Long COVID Disappointment
- What Caregivers Should Have Ready Before an Infection Hits
- Where COVID Antivirals Go From Here
- Conclusion
- Frequently Asked Questions
How Does Paxlovid Cut COVID Hospitalization Risk by 89%?
The 89% figure comes from Pfizer’s EPIC-HR trial, formally called the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients. The final study data, drawn from 2,246 participants, confirmed that number. When patients started treatment within three days of their first symptoms, just 3 out of 389 people taking paxlovid ended up in the hospital, versus 27 out of 385 on placebo. Even when the treatment window was extended to five days after symptom onset, the reduction held at 88%, with 6 hospitalizations out of 607 patients and zero deaths in the Paxlovid group, compared to 41 hospitalizations and 10 deaths among 612 placebo patients. The drug works by combining two active ingredients. Nirmatrelvir is a protease inhibitor that blocks the virus from copying itself inside your cells.
Ritonavir, originally developed as an HIV medication, slows the breakdown of nirmatrelvir in the body, keeping it active longer. The regimen is three pills taken twice daily for five days, and it can be taken at home — no infusion center visit required. For a caregiver managing someone with dementia who may already struggle with hospital visits, that home-based treatment is a meaningful practical advantage. It is worth comparing this to the alternative. Before Paxlovid, the primary early treatment options were monoclonal antibody infusions, which required clinic visits and eventually lost effectiveness against newer variants. Paxlovid offered something genuinely different: an oral pill that a patient could take on their couch. For a person with dementia, who may become agitated or confused in unfamiliar medical settings, avoiding a hospital trip is not just convenient — it can prevent a cascade of behavioral and cognitive complications.
Real-World Effectiveness in Vaccinated and Older Adults
The original trial data is striking, but it reflects a world that no longer exists. Those participants were unvaccinated, had never been infected, and were studied during the pre-Omicron era of the pandemic. Most older adults in 2025 have some combination of vaccination and prior infection, which changes the math considerably. UCLA Health research found that among vaccinated older adults, Paxlovid’s impact on hospitalization was at best four times weaker than the headline 89% figure. That does not mean the drug is useless — far from it.
Studies reviewed by CIDRAP confirm that Paxlovid still lowers hospitalization risk, reduces deaths, decreases medical visits, and speeds symptom recovery even in people with prior immunity. However, if your loved one is fully vaccinated and has had a previous COVID infection, the benefit of Paxlovid is real but more modest than a press release might suggest. For caregivers of people with dementia, the calculation still tends to favor treatment. Dementia itself is a risk factor for severe COVID outcomes, and older adults with cognitive impairment are more likely to have comorbidities like heart disease and diabetes that compound their vulnerability. Even a smaller absolute reduction in hospitalization risk can be clinically meaningful when the baseline risk is already elevated. The key is having realistic expectations: Paxlovid is not a guarantee against severe illness, but it tilts the odds in a favorable direction.
Why Timing Matters More Than Anything Else
The single most important variable in Paxlovid’s effectiveness is when treatment starts. The drug must be initiated within five days of symptom onset, and the trial data showed better results at the three-day mark. For someone with dementia, this creates a specific challenge: the person may not recognize or communicate early symptoms reliably. Consider a common scenario. A person with moderate Alzheimer’s disease develops a mild cough and low-grade fever. They may not mention it, or they may describe it vaguely.
By the time a caregiver notices something is off — perhaps through changes in behavior, appetite, or energy level — two or three days may have already passed. If another day goes by waiting for a test result and a doctor’s call, the treatment window can close entirely. This is why many geriatricians recommend that caregivers of high-risk individuals keep rapid COVID tests on hand and test at the first sign of any respiratory symptom, behavioral change, or unexplained decline. Once a positive test is confirmed, the next step is contacting the prescribing physician immediately. Many primary care offices and telehealth services can prescribe Paxlovid quickly, sometimes within hours. Some pharmacists can also prescribe it directly. The goal is to get those first pills taken as close to symptom onset as possible, because every day of delay reduces the drug’s protective effect.
Drug Interactions Caregivers Must Watch For
Paxlovid’s ritonavir component is a powerful inhibitor of certain liver enzymes, which means it interacts with a long list of other medications. For people with dementia, who often take multiple prescriptions, this is not a minor concern — it is the single biggest practical obstacle to treatment. Common medications that interact with ritonavir include certain blood thinners like rivaroxaban, cholesterol-lowering statins like lovastatin and simvastatin, some heart rhythm drugs, sedatives like midazolam, and several seizure medications. Some of these interactions are dangerous enough that the medications cannot be taken together at all. Others require temporary dose adjustments.
For a person with dementia who may also be on cholinesterase inhibitors like donepezil or memantine, the interaction profile needs to be checked carefully, though these specific dementia drugs are not among the most problematic combinations. The tradeoff is real. In some cases, a physician may decide that the interaction risk outweighs the benefit of Paxlovid, particularly if the patient is vaccinated and their COVID symptoms are mild. In other cases, a short pause on a conflicting medication may be possible. This decision should involve the prescribing doctor, the patient’s neurologist or geriatrician, and ideally a pharmacist who can review the full medication list. Do not attempt to adjust medications on your own — the interactions can be unpredictable and serious.
The Rebound Problem and Long COVID Disappointment
Two limitations of Paxlovid deserve honest attention. The first is viral rebound. Some patients who complete the standard five-day course experience a return of symptoms and positive test results days after finishing treatment. This does not mean the drug failed — it may reflect incomplete viral clearance, particularly in people with weakened immune systems. For immunocompromised patients, studies have shown that extended courses of 10 to 15 days can reduce this rebound compared to the standard five-day regimen. The second limitation is more consequential for the dementia care community. A study published in The Lancet Infectious Diseases in April 2025 found that Paxlovid was not effective at relieving Long COVID symptoms.
This is a significant finding because Long COVID has been linked to cognitive decline, brain fog, and worsening of existing dementia symptoms. Many caregivers and clinicians had hoped that early antiviral treatment might prevent the neurological aftermath of infection. Based on current evidence, that hope has not been realized. Paxlovid appears to help with the acute phase of illness — keeping people out of the hospital and alive — but it does not reliably prevent the lingering effects that can be so damaging to brain health. This does not mean early treatment is pointless for brain protection. Avoiding severe illness and hospitalization has its own cognitive benefits. Delirium during hospitalization is one of the strongest predictors of accelerated dementia progression, and anything that prevents a hospital stay may indirectly protect cognitive function. But caregivers should not count on Paxlovid as a shield against Long COVID specifically.
What Caregivers Should Have Ready Before an Infection Hits
Preparation makes the difference between catching the treatment window and missing it. Keep a supply of rapid antigen tests in the home and check their expiration dates regularly. Have a written, up-to-date medication list for the person you care for, including dosages and prescribing doctors, so that a physician evaluating Paxlovid eligibility can quickly assess drug interactions.
Know your pharmacy’s ability to fill Paxlovid prescriptions — not every location keeps it in stock, and a delay of even one day matters. It also helps to establish a relationship with a telehealth provider or confirm that your loved one’s primary care doctor can do same-day prescribing. Some caregivers have found it useful to discuss Paxlovid eligibility with the physician in advance, during a routine visit, so that when an infection occurs, the conversation is about execution rather than evaluation.
Where COVID Antivirals Go From Here
Paxlovid is not the end of the story. Researchers continue to study next-generation antivirals that may work against a broader range of variants, have fewer drug interactions, and potentially address Long COVID prevention — something Paxlovid has not delivered on. The virus itself continues to evolve, and the effectiveness of any antiviral will need ongoing reassessment against new strains.
For the dementia care community, the broader lesson is that COVID remains a meaningful threat to brain health, even in an era of widespread immunity. Antivirals like Paxlovid are one layer of protection, not a complete solution. Vaccination, good infection control practices in care settings, and rapid response to early symptoms all work together. The 89% figure from the original trial captured attention for good reason, but the real-world picture is more nuanced, and caregivers who understand that nuance are better positioned to protect the people they look after.
Conclusion
Paxlovid remains the most effective oral antiviral available for reducing COVID-19 hospitalization and death, though its real-world benefit in vaccinated and previously infected older adults is more modest than the original 89% trial result suggested. For people with dementia, the drug’s value extends beyond the direct antiviral effect — avoiding hospitalization can help prevent delirium and the cognitive deterioration that often follows. The critical factors are timing, drug interaction management, and realistic expectations about what the medication can and cannot do.
Caregivers should focus on preparation: keep tests available, maintain current medication lists, and establish prescribing relationships before they are needed. Understand that Paxlovid does not prevent Long COVID based on current evidence, and that rebound symptoms are possible. Despite these limitations, when started early in a high-risk patient, Paxlovid shifts the odds meaningfully in the right direction. In dementia care, where every hospitalization carries outsized cognitive risk, that shift matters.
Frequently Asked Questions
Can a person with dementia take Paxlovid safely?
Yes, in most cases. The main concern is drug interactions, not dementia itself. A physician should review the person’s full medication list before prescribing. Dementia medications like donepezil and memantine are not among the most problematic interactions, but every case should be evaluated individually.
What if my loved one cannot swallow pills easily?
Paxlovid comes as tablets that must be swallowed. They should not be crushed, split, or chewed without medical guidance. If swallowing is a concern, discuss alternatives with the prescribing doctor — though options beyond Paxlovid are limited for home-based oral treatment.
Does Paxlovid prevent Long COVID brain fog?
Based on a study published in The Lancet Infectious Diseases in April 2025, Paxlovid was not effective at relieving Long COVID symptoms. There is currently no strong evidence that it prevents the cognitive effects associated with Long COVID.
How quickly does Paxlovid need to be started?
Within five days of symptom onset, though data from the EPIC-HR trial showed better outcomes when treatment began within three days. For dementia patients who may not report symptoms early, caregivers should test at the first sign of any change in behavior, energy, or respiratory health.
Is the 89% figure still accurate today?
The 89% reduction was observed in unvaccinated, previously uninfected, high-risk patients during the pre-Omicron period. UCLA Health research found the effect in vaccinated older adults is at best four times weaker. The drug still provides benefit for high-risk individuals, but the real-world reduction is smaller than the original headline number.
Is Paxlovid still available and recommended in 2025?
Yes. Paxlovid is FDA-approved for patients age 12 and older who are at risk for severe COVID-19. It remains the standard go-to oral antiviral for COVID-19 treatment as of 2025.
